An increased prevalence of CHIP has been observed following cytotoxic therapies such as chemotherapy, radiotherapy, and PARP inhibitor therapy (38–41), suggesting that these treatments contribute to the emergence and expansion of mutated cells in the hematopoietic system, thereby fostering the development of therapy-related myeloid neoplasms (t-MNs). The gene discussed is STUB1; the disease is myeloid neoplasm.